March: Securing Mobile Devices #securing #mobile #devices, #march: #securing #mobile #devices

Posted On Sep 30 2017 by

# March: Securing Mobile Devices Sample Tweets, Posts, and Materials to Promote Mobile Security Authors: by Christina Bonds Published: Monday, December 14, 2015 Columns: Security Matters Campus Security Awareness Campaign 2016 This post is part of a larger campaign designed to support security professionals and IT communicators as they develop or enhance their security awareness plans. View the other monthly blog posts with ready-made content, as well as a printable calendar with the 12 topics. Learn more. Mobile device theft is on the rise. Educate your end users about what they can do now to secure and protect their data …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #pharmaceutical #wholesalers

Posted On Sep 8 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #pharma #job #search

Posted On Aug 28 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #generic #pharmaceutical

Posted On Aug 2 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #cadence #pharma

Posted On Jul 10 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #top #10 #pharma #companies

Posted On May 31 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #new #pharmaceutical #companies

Posted On Apr 2 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #ipca #pharma

Posted On Mar 20 2017 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #pharmaceutical #companies

Posted On Dec 14 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …


Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 #amag #pharma

Posted On Nov 23 2016 by

#pharmaceutical companies in houston tx # Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009 On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances …